Table 1.
Clinical trials targeting stroma in cancer; all trials vs. trials that are active, recruiting patients and not yet recruiting were included in this table.
| Clinical Trials Cancer Only Trials | |||
|---|---|---|---|
| Target | Compound | # of all Trials: | # of Active, Recruiting and Not yet recruiting trials: |
| Vitamin D | Vitamin D, not specified | 396 | 114 |
| Paricalcitol | 43 | 12 | |
| Cholecalciferol | 141 | 40 | |
| Hyaluronan | PEGPH20 | 22 | 13 |
| Integrins | Integrin targeting trials | 146 | 53 |
| Src | Src targeting, other | 117 | 37 |
| Saracatinib | 26 | 1 | |
| FAK | FAK targeting, not specified | 41 | 12 |
| Defactinib/VS-6063 | 14 | 6 | |
| TGFβ | TGFβ targeting trials, not specified | 168 | 77 |
| Losartan | 12 | 6 | |
| Galunisertib | 21 | 12 | |
| AVID200 | 2 | 2 | |
| Fresolimumab | 7 | 1 | |
| LY3200882 | 3 | 3 | |
| Vactosertib | 8 | 7 | |
| Anti-PD-L1/TGFβRII Fusion Protein M7824 | 17 | 16 | |
| CXCR4 | CXCR4 | 61 | 27 |
| CXCL12/SDF1a | CXCL12/SDF1a | 45 | 14 |
| CSF1 | All CSF1 targeting trials | 256 | 95 |
| CSF1R | All CSF1R targeting trials | 42 | 30 |
| VEGF | Sevacizumab | 3 | 1 |
| Avastin/Bevacizumab | 1912 | 488 | |
| Vanucizumab (angiopoetin) | 4 | 2 | |
| Cabozantinib (c-MET, VEGFR2, AXL, RET) | 145 | 108 | |
| Axitinib | 131 | 51 | |
| Regorafenib | 171 | 89 | |
| Apatinib | 287 | 194 | |
| IBI305 | 38 | 35 | |
| Ramucirumab | 112 | 63 | |
| Cediranib | 103 | 30 | |
| CTGF | Pamrevlumab | 1 | 1 |